title: [Inhibitory effect of selenium on complement activation and its clinical significance].
abstract: In immunopathological study of complement activation, we recognised a marked inhibitory effect of sodium selenite on the haemolysis induced by complement fixation in vitro, thereafter on mouse complement activation in vivo induced by endotoxin, inulin or aggregated IgG indicated by a special rocket immunoelectrophoresis test of C3 split products. The effective inhibition usually began at the concentration of 0.002 mol/L of selenite in vitro, and 20 micrograms/25 g BW intravenously in vivo. The inhibitory effect was found evident on alternative pathway. This inhibitory effect was further identified in cases of epidemic haemorrhagic fever (EHF) treated by multiple dosages of 2 mg selenite per day in the first 9 days of hospitalization other than general management of 80 severe cases, including fulminant and moderate grade EHF cases. C3 activation was inhibited accordingly and the mortalities also dropped markedly from 100% of the non-treated group to 36% of the selenite treated group of fulminant type, and from 22% to zero of severe type group.
authors.affiliation: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing.
authors.forename: J C
authors.initials: JC
authors.lastname: Hou
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Jiang
authors.forename: Z F
authors.initials: ZF
authors.lastname: He
mesh_terms: D000936:Antigen-Antibody Complex / Q000097:blood; D003167:Complement Activation / Q000187:drug effects*; D003176:Complement C3; D003170:Complement Pathway, Alternative / Q000187:drug effects; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008297:Male; D012643:Selenium / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000936:Antigen-Antibody Complex; D003176:Complement C3; D012643:Selenium